Key Points
- Director Luke Evnin sold 22,184 shares of Werewolf Therapeutics at an average price of $0.50, worth about $11,092, as part of a pre-arranged Rule 10b5-1 trading plan. After the sale, he still held 1,104,312 shares.
- Evinn has been actively reducing his stake through a series of recent sales, including large transactions on May 1, May 8, and May 20. The repeated selling coincides with the stock trading near its 52-week low.
- Werewolf Therapeutics remains under pressure despite a small earnings beat, with the stock around $0.44, a market cap of about $21.3 million, and analysts holding an overall Hold rating with a $3.75 average price target.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 22,184 shares of the company's stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $0.50, for a total value of $11,092.00. Following the completion of the transaction, the director owned 1,104,312 shares of the company's stock, valued at approximately $552,156. This represents a 1.97% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Luke Evnin also recently made the following trade(s):
- On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.43, for a total value of $36,934.85.
- On Tuesday, May 19th, Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total value of $28,336.50.
- On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $43,446.40.
- On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total value of $22,745.16.
- On Friday, May 8th, Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.70, for a total value of $214,018.70.
- On Thursday, May 7th, Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $49,824.18.
- On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.66, for a total value of $9,659.10.
- On Tuesday, May 5th, Luke Evnin sold 6,860 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total value of $4,733.40.
- On Monday, May 4th, Luke Evnin sold 47,963 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.72, for a total value of $34,533.36.
- On Friday, May 1st, Luke Evnin sold 58,394 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.73, for a total value of $42,627.62.
Werewolf Therapeutics Trading Up 2.2%
Werewolf Therapeutics stock opened at $0.44 on Thursday. The stock has a market cap of $21.29 million, a P/E ratio of -0.35 and a beta of 0.41. The stock has a 50 day moving average of $0.79 and a 200-day moving average of $0.79. Werewolf Therapeutics, Inc. has a 52 week low of $0.40 and a 52 week high of $2.38.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. As a group, equities analysts predict that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Werewolf Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in HOWL. Jane Street Group LLC acquired a new stake in Werewolf Therapeutics in the second quarter worth $409,000. Renaissance Technologies LLC increased its position in Werewolf Therapeutics by 48.6% in the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company's stock worth $429,000 after buying an additional 221,766 shares during the period. Citadel Advisors LLC acquired a new stake in Werewolf Therapeutics in the third quarter worth $304,000. Vanguard Group Inc. increased its position in Werewolf Therapeutics by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company's stock worth $2,774,000 after buying an additional 109,796 shares during the period. Finally, Marshall Wace LLP acquired a new stake in Werewolf Therapeutics in the second quarter worth $113,000. 64.84% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research firms recently issued reports on HOWL. Weiss Ratings reissued a "sell (d-)" rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Wall Street Zen lowered Werewolf Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Werewolf Therapeutics presently has an average rating of "Hold" and an average price target of $3.75.
View Our Latest Report on HOWL
Werewolf Therapeutics Company Profile
(
Get Free Report)
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company's proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
